Furthermore, the efficacy in squamous NSCLC, as demonstrated in the ASTRUM-004 trial, fills an important niche, as treatment options for this subtype have historically been more limited compared to non-squamous carcinomas (11) The consistency of benefit across different PD-1/PD-L1 inhibitors (atezolizumab, serplulimab, camrelizumab) supports a class-effect phenomenon for this combination strategy, reinforcing the robustness of this therapeutic approach (4, 6). The gene discussed is CD274; the disease is squamous cell carcinoma.